Skip to main content
. 2016 May 20;52(2):91–100. doi: 10.4068/cmj.2016.52.2.91

TABLE 5. Summary of published (Phase III) clinical trials investigating efficacy of vilazodone in patient with generalized anxiety disorder.

graphic file with name cmj-52-91-i005.jpg

aNumber of total intent-to-treat patients, bBased on mean change from baseline to end-of-double blind phase (Week 8) using mixed-effects model for repeated measures.

*p<0.05.

HAM-A: Hamilton rating scale for anxiety, ITT: intent to treat, RCT: randomized double-blind placebo controlled trials, PBO: placebo, SD: standard deviation, SE: standard error, VLD: vilazodone.